INTENSITY THERAPEUTICS, INC. Q2 2026: Net income $(3.0M), EPS $(1.11) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Intensity Therapeutics reported a Q2 2026 net loss of $3.0M and diluted EPS of $(1.11), widening from the prior year's $2.5M loss. The company remains pre-revenue. Clinically, it initiated Phase 3 INVINCIBLE-3 and Phase 2 INVINCIBLE-4 trials, with FDA agreement on CMC plans for Phase 3 and NDA. However, funding constraints have paused broader site activations, limiting U.S. resumption pending additional capital.
INTENSITY THERAPEUTICS, INC. reported a consolidated net loss of $(3.0M) for the second quarter of 2026, compared with a $(2.5M) loss in the year-ago quarter; diluted loss per share was $(1.11) versus $(3.36) in Q2 2025. The company remains pre-revenue with no product or licensing revenue recognized for the quarter.
Financial Highlights
- Revenue: Not reported for Q2 2026 (no product or licensing revenue; company remains pre-revenue).
- Net income: $(3.0M) for Q2 2026, compared with $(2.5M) in Q2 2025; deterioration of $0.47M year-over-year.
- Diluted EPS: $(1.11) for Q2 2026, compared with $(3.36) in Q2 2025.
Business Highlights
- Clinical program progress: Completed Phase 1/2 IT-01 and Phase 2 INVINCIBLE-2; initiated Phase 3 INVINCIBLE-3 and Phase 2 INVINCIBLE-4 with periods of paused and resumed enrollment.
- Operations and manufacturing: Developed Phase 3 analytical methods and manufactured multiple large-scale GMP batches of INT230-6.
- Regulatory engagement: FDA agreed on the CMC plan for Phase 3 and an NDA; INVINCIBLE-3 received authorization from the FDA, Health Canada, EMA and TGA.
- Trial outcomes and biomarkers: INVINCIBLE-2 showed high tumor necrosis and immune activation; early INVINCIBLE-4 data indicated higher pathological complete response (pCR) rates and fewer grade 3 adverse events in the treatment arm.
- Funding and enrollment impact: Funding constraints paused broader site activations, with limited U.S. resumption planned pending incremental capital.
Original SEC Filing: INTENSITY THERAPEUTICS, INC. [ INTS ] - 10-Q - Aug. 11, 2026